The two scientists won the European Inventor Award jointly in the SMEs category from the European Patent Office (EPO) for their vaccine assembly platform, the office announced on Tuesday.
The vaccine could be used to treat different types of cancer, boosting the immune system’s response to the disease and offering new hope for cancer treatment, the EPO saidExternal link.
“Derouazi and Belnoue’s invention assembles three essential components of a vaccine into a single protein [……] to produce vaccines for different types of cancer. They are intended for use alongside treatments such as surgery, chemotherapy and radiotherapy,” the EPO said.
The KISIMA platform was first used to produce a vaccine designed to treat metastatic colorectal cancer, and early-stage human trials are underway.
Derouazi studied biology and biotechnology in Geneva, Berlin and Lausanne before completing a post-doc at the French National Center for Scientific Research in Paris.
Launched in 2006, the award, which is attributed in five different categories, honours individuals and team solutions to some of the biggest challenges, the EPO said.
Employees in Switzerland increasingly stressed at work
This content was published on
The proportion of people in Switzerland who are stressed at work has increased by 5% over ten years, according to the Federal Statistical Office.
This content was published on
F/A-18 fighter jets will practice take offs and landings on the A1 motorway between Payerne and Avenches in canton Vaud on June 5.
Swisscom finalises financing for Vodafone Italia takeover
This content was published on
Telecoms group Swisscom has taken the next step in its takeover of Vodafone Italia and secured financing for the deal, the company said on Thursday.
Switzerland commits CHF50 million to combat rural poverty worldwide
This content was published on
The Federal Council approved a contribution of CHF49.5 million ($54.1 million) for the International Fund for Agricultural Development (IFAD).
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.